Skip NavigationSkip to Content
Return Return to Search Results

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines

  1. Author:
    Condit, Richard C
    Kim, Denny
    Robertson, James S
    Excler, Jean-Louis
    Gurwith, Marc
    Monath, Thomas P
    Pavlakis,George
    Fast, Patricia E
    Smith, Jonathan
    Smith, Emily R
    Chen, Robert T
    Kochhar, Sonali

  2. Author Address

    Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA., Janssen Pharmaceuticals, Titusville, NJ, USA., Independent Adviser, United Kingdom., International Vaccine Institute, Seoul, Republic of Korea., Brighton Collaboration, a Program of the Task Force for Global Health, Decatur, GA, USA., Crozet BioPharma LLC, Devens, MA 01434, USA., National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA., International AIDS Vaccine Initiative, New York, NY 10004, USA; Stanford School of Medicine, Palo Alto, CA 94305, USA., VLP Therapeutics, Gaithersburg, MD 20878, USA., Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA 98195, USA.,
    1. Year: 2020
    2. Date: NOV 17
    3. Epub Date: 2020 09 06
  2. Journal: Vaccine
    1. 38
    2. 49
    3. Pages: 7708-7715
  4. Type of Article: Article
  5. ISSN: 0264-410X
  1. Abstract:

    Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety Working Group, V3SWG) working group has prepared a standardized template to describe the key considerations for the benefit-risk assessment of viral vector vaccines. This will facilitate key stakeholders to anticipate potential safety issues and interpret or assess safety data. This would also help improve communication and public acceptance of licensed viral vector vaccines. Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.vaccine.2020.08.009
  3. PMID: 32907759
  4. View record in Web of Science®
  5. WOS: 000588128100003
  6. PII : S0264-410X(20)31030-6

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel